Stockreport

Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma [Yahoo! Finance]

Humacyte, Inc.  (HUMA) 
PDF – The HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks – – PDUFA date set for August 10, [Read more]